BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
95.03
+0.89 (0.95%)
Dec 24, 2025, 4:00 PM EST - Market closed
BioNTech SE Employees
BioNTech SE had 6,772 employees as of December 31, 2024. The number of employees increased by 639 or 10.42% compared to the previous year.
Employees
6,772
Change (1Y)
639
Growth (1Y)
10.42%
Revenue / Employee
$546,192
Profits / Employee
-$99,034
Market Cap
22.85B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | 1,941 | 631 | 48.17% |
| Dec 31, 2019 | 1,310 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BNTX News
- 6 days ago - BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field - GlobeNewsWire
- 14 days ago - BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart - Seeking Alpha
- 15 days ago - BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer - GlobeNewsWire
- 17 days ago - BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer - GlobeNewsWire
- 21 days ago - BioNTech Achieves Minimum Condition in CureVac Exchange Offer - GlobeNewsWire
- 22 days ago - FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks - Investopedia
- 23 days ago - Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men - Market Watch
- 4 weeks ago - BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration - GlobeNewsWire